Kristina R Dahlstrom1, Juhee Song2, Peter F Thall2, Clifton D Fuller3, Katherine A Hutcheson1, Faye M Johnson4,5, G Brandon Gunn3, Jack Phan3, Steven J Frank3, William H Morrison3, Renata Ferrarotto4, David I Rosenthal3, Erich M Sturgis6, Adam S Garden3. 1. Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas. 3. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 4. Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 5. University of Texas Graduate School of Biomedical Sciences, Houston, Texas. 6. Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, Texas.
Abstract
BACKGROUND: Risk of recurrence among patients with oropharyngeal cancer (OPC) who survive 5 years is low. The goal of this study was to assess long-term survival of patients with OPC alive without recurrence 5 years after diagnosis. METHODS: This study included newly diagnosed patients with OPC, who had been treated with radiation and were alive without recurrence 5 years after diagnosis. Overall survival (OS) probabilities beyond 5 years were estimated using the Kaplan-Meier method. Factors associated with OS were determined using Bayesian piecewise exponential survival regression. Standardized mortality ratios for all-cause death were estimated controlling for study year, age, and sex in the US general population. RESULTS: Among 1699 patients, the additional 2-year, 5-year, and 10-year OS probabilities were 94%, 83%, and 63%, respectively, and were lower than those in the general population. Patients who were older, were current or former smokers, had other than tonsil or base of tongue tumors, or had T4 tumors had a higher risk of death. Patients who had base of tongue tumors and had received intensity-modulated radiation therapy (IMRT) or lower-radiation doses had a lower risk of death. Standardized mortality ratios were higher among current and heavy smokers and lower among recipients of IMRT and lower radiation doses. CONCLUSIONS: In this large cohort, long-term survival among patients with OPC was good but lower than predicted for the general population. Patients treated with IMRT and those with less tobacco exposure had better outcomes.
BACKGROUND: Risk of recurrence among patients with oropharyngeal cancer (OPC) who survive 5 years is low. The goal of this study was to assess long-term survival of patients with OPC alive without recurrence 5 years after diagnosis. METHODS: This study included newly diagnosed patients with OPC, who had been treated with radiation and were alive without recurrence 5 years after diagnosis. Overall survival (OS) probabilities beyond 5 years were estimated using the Kaplan-Meier method. Factors associated with OS were determined using Bayesian piecewise exponential survival regression. Standardized mortality ratios for all-cause death were estimated controlling for study year, age, and sex in the US general population. RESULTS: Among 1699 patients, the additional 2-year, 5-year, and 10-year OS probabilities were 94%, 83%, and 63%, respectively, and were lower than those in the general population. Patients who were older, were current or former smokers, had other than tonsil or base of tongue tumors, or had T4 tumors had a higher risk of death. Patients who had base of tongue tumors and had received intensity-modulated radiation therapy (IMRT) or lower-radiation doses had a lower risk of death. Standardized mortality ratios were higher among current and heavy smokers and lower among recipients of IMRT and lower radiation doses. CONCLUSIONS: In this large cohort, long-term survival among patients with OPC was good but lower than predicted for the general population. Patients treated with IMRT and those with less tobacco exposure had better outcomes.
Authors: Stefanie Hieke; Martina Kleber; Christine König; Monika Engelhardt; Martin Schumacher Journal: Clin Cancer Res Date: 2015-04-01 Impact factor: 12.531
Authors: Puja Aggarwal; Jhankruti S Zaveri; Ryan P Goepfert; Qiuling Shi; Xianglin L Du; Michael Swartz; G Brandon Gunn; Stephen Y Lai; C David Fuller; Ehab Y Hanna; David I Rosenthal; Jan S Lewin; Linda B Piller; Katherine A Hutcheson Journal: JAMA Otolaryngol Head Neck Surg Date: 2018-11-01 Impact factor: 6.223
Authors: Puja Aggarwal; Jhankruti S Zaveri; Ryan P Goepfert; Qiuling Shi; Xianglin L Du; Michael Swartz; Stephen Y Lai; C David Fuller; Jan S Lewin; Linda B Piller; Katherine A Hutcheson Journal: Head Neck Date: 2019-08-23 Impact factor: 3.147
Authors: Ryan P Goepfert; Jan S Lewin; Martha P Barrow; G Brandon Gunn; C David Fuller; Beth M Beadle; Adam S Garden; David I Rosenthal; Merrill S Kies; Vassiliki Papadimitrakopoulou; Stephen Y Lai; Neil D Gross; David L Schwartz; Katherine A Hutcheson Journal: Int J Radiat Oncol Biol Phys Date: 2016-06-15 Impact factor: 7.038
Authors: Carole Fakhry; William H Westra; Sigui Li; Anthony Cmelak; John A Ridge; Harlan Pinto; Arlene Forastiere; Maura L Gillison Journal: J Natl Cancer Inst Date: 2008-02-12 Impact factor: 13.506
Authors: Jolie Ringash; Richard Fisher; Lester Peters; Andy Trotti; Brian O'Sullivan; June Corry; Lizbeth Kenny; Sandra Nuyts; Chris Wratten; Danny Rischin Journal: Int J Radiat Oncol Biol Phys Date: 2016-03-23 Impact factor: 7.038
Authors: Erin Arthurs; Timothy P Hanna; Khaled Zaza; Yingwei Peng; Stephen F Hall Journal: Int J Radiat Oncol Biol Phys Date: 2016-07-17 Impact factor: 7.038
Authors: Shivani Shah-Becker; Michael Pennock; Lawrence Sinoway; David Goldenberg; Neerav Goyal Journal: Head Neck Date: 2017-07-04 Impact factor: 3.147
Authors: Arlene A Forastiere; Qiang Zhang; Randal S Weber; Moshe H Maor; Helmuth Goepfert; Thomas F Pajak; William Morrison; Bonnie Glisson; Andy Trotti; John A Ridge; Wade Thorstad; Henry Wagner; John F Ensley; Jay S Cooper Journal: J Clin Oncol Date: 2012-11-26 Impact factor: 44.544